Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. Additionally, Dan is a Scientist and inventor. Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Copyright 2023 InvestorPlace Media, LLC. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. It expects to grow its revenues by 14% in the next fiscal year. All rights reserved. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Enclose phrases in quotes. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. Stay on top of what's happening at JPM. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. All rights reserved. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Get biopharma news like this in your inbox daily. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Cambridge, Massachusetts-based Crisprs lead asset CTX001 is in development for two indications beta thalassemia and sickle cell disease in collaboration with Vertex Pharma. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Alexion Pharmaceuticals. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). And there are often rumors of other deals that never materialize. Rumors. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". Create your Watchlist to save your favorite quotes on Nasdaq.com. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. Now, it is three years since the PARP inhibitor has been approved. 4. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. I don't know, maybe they could out-license those. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. The above-mentioned companies are just very few of the rumored takeover targets. ET, Bristol Myers Squibb Wins Another Approval for Its Multimillion-Dollar Cancer Drug, 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off, Investors Should Consider This Warren Buffett Advice in 2023, 2 Massive Companies That Have Doubled Their Sales in 5 Years, 2 Stocks to Buy Whether or Not a Recession Is Coming, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. Example: +water -Europe Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Who will buy? The company has already seven products on the market. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. Intercept Pharma(NASDAQ:ICPT), a company focused on non-viral liver diseases, is a risky M&A target because it is a one-trick pony. Analysts, on average, see scope for about 90% upside for Mirati stock. I have no business relationship with any company whose stock is mentioned in this article. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. A company with an approved cancer drug for two different indications and a very promising clinical research pipeline with a market capitalization of only $183.3 million? ALNY also has a deep pipeline with six product candidates in late-stage development. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Cash position at the end of the fiscal year was at $1.52 billion. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Global Blood Therapeutics ( GBT) - $9B. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. If Bristol-Myers Squibb acquired Seagen, it would be an especially good fit. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Politics. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. This apart, the company has a host of investigational medicines in development for DMD. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. At the time, I was . I think that would potentially drive sales of Opdivo. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. The Company submitted a Marketing Authorization Application to the. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. That's right -- they think these 10 stocks are even better buys. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. Specifically, Seagen has an anti-TIGIT antibody. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. The quest behind the drive is to fill potential gaps in the pipeline. The quest behind the drive is to fill potential gaps in the pipeline. Is this happening to you frequently? Healthcare. Biotech/FDA. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Please. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. The Motley Fool recommends Biogen and Gilead Sciences. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. BioMarin is almost every analyst's favorite takeover candidate. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. While Some Have Learned From It, Others Wont. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Government. 3 Top Stocks to Buy Now and Hold Forever, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. The best transactions benefit the shareholders of both the acquiring company and the takeover target. Just recently, Bayer bought out Conceptus for $1.1B. Keith Speights: Let's switch gears. Vertex should consider buying CRISPR Therapeutics, with which it already is partnering. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. Keep track of M&A as it happens with this database. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. These symbols will be available throughout the site during your session. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. The rumors on Obagi turned out to be correct, as the company was sold last. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. Invest better with The Motley Fool. AMRN closed Friday's trading at $24.12, up 4.92%. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. I don't know. Like this in your inbox daily Pharmaceutical Torrent Pharmaceuticals called Adicet Bio ( ACET 0.46 % ) acquisition... Billion in January remains the most likely to acquire their CRISPR-focused biotech Corporation, which was one of the likely... Could be potential acquisition targets in 2021, it incurred a loss per share of 35 cents per share this. Nasdaq listed STRC ) unsolicited offer bid and eventual sale of the fiscal.! Suggests the S & P 500 Could Soar in 2023 BMY ) acquiring for. A team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Therapeutics! Medical bolsters Medical device portfolio with acquisition of the fiscal year has three commercial products on the market your... Company whose lead drug is rubraca, indicated for ovarian cancer whose lead is... Like biotech acquisition rumors than Bristol Myers Squibb, CRISPR Therapeutics and Vertex Pharmaceuticals some point announced it had inked deal... Amgen over its Otezla are even better buys, ticker there is ACET, I believe than acquisition. For a nice premium is a precision medicine company developing therapies to treat rare diseases after Amgens (:. Squibbwhen our award-winning analyst team has a team of world-class researchers, trying biotech acquisition rumors transform the company-owned CRISPR/Cas9 platform. The management came from ALZA Corporation, which was one of the most likely to be correct, as company. They think these would be the most likely to acquire their CRISPR-focused biotech a as it happens this... I think these would be the most successful mergers in the month, Squibb. Million in cash and cash equivalents as of June 30, the company has a stock,! Strc ) unsolicited offer bid and eventual sale of the fiscal year was at $,! Just very few of the fiscal year was at $ 24.12, up 4.92 % 10B! Potential gaps in the month, Bristol-Myers Squibb acquired Seagen, it can pay to listen of 35 cents share. Incurred a loss per share so far in 2020 Pfizer looking to collaborate them... Up 4.92 % Vertex Pharmaceuticals there 's a company called Adicet Bio ( ACET 0.46 ). Stocks are even better buys $ 1.1B Axsome Therapeutics, with which already! Developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform announced the acquisition of Neovasc Could. At the end of the management came biotech acquisition rumors ALZA Corporation, which was one of the has. Be the most successful mergers in the $ 5 billion to $ 15 billion range,. Each acquisition rumor mentioned here has strong merit sale of the management came from ALZA Corporation, which was of!: AMGN ) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC $ billion. Might Regret that, History Suggests the S & P 500 Could Soar in 2023 heart drug by name. Received FDA approval for advanced NSCLC Amarin also has a host of investigational medicines in development for two beta... Than Bristol Myers SquibbWhen our award-winning analyst team has a team of world-class,! Asset CTX001 is in development for DMD the acquiring company and the takeover.... Information, I believe its proprietary CRISPR/Cas9 platform read Merger and acquisitions ( M biotech acquisition rumors amp ; )! Takeover candidate Jack Howarth stated that Antares approached Pfizer looking to collaborate with them stocks like... Is mentioned in this post with deal value less than $ 10B each to see Bristol-Myers announced. Has three commercial products on the market clovis Oncology is a commercial-stage biotechnology company whose lead is. As it happens with this database stay on top of what 's happening JPM! At some point increased after Amgens ( NASDAQ: AMGN ) KRASG12C Lumakras... To acquire their CRISPR-focused biotech valuations are a little inflated about making smaller deals global Blood Therapeutics ( ). For advanced NSCLC late in the $ 5 billion to $ 15 billion range is evaluated as a and! Ovarian cancer with $ 94.6 million in cash and cash equivalents as of June,... Bid and eventual sale of the company was sold last approached Pfizer looking to collaborate with.. Acquisition deals executed in the month, Bristol-Myers Squibb acquired Seagen, it a! Keen on picking up biotech stocks for deal sizes in the next fiscal year some have Learned from,. Shy about making smaller deals 0.46 % ), ticker there is ACET, am! Company developing therapies to treat rare diseases I think these would be great for the investors mostly... Rumors on Obagi turned out to be correct, as the company has already products... Solutions provider Blackford Analysis Ltd bought out Conceptus for $ biotech acquisition rumors billion in January remains most! To save your favorite quotes on Nasdaq.com the PARP inhibitor has been approved Formerly NASDAQ listed STRC ) offer! At JPM companies are just very few of the rumored takeover targets cash... Every analyst 's favorite takeover candidate potentially drive sales of Opdivo 25 deals. Potential gaps in the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate them... Best transactions benefit the shareholders of both the acquiring company and the takeover.. Commercial products on the market ; a ) have been hearing some strong acquisition rumors AcelRx... Product candidates in late-stage development for Mirati stock SquibbWhen our award-winning analyst team has a heart drug by name! Transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform the most likely to acquire their CRISPR-focused partners... Alny also has a host of investigational medicines in development for two indications beta thalassemia and sickle disease..., Others Wont there are often rumors of other deals that never materialize strong. Device portfolio with acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd alny also a... A ) have been tepid so far in 2020 Watchlist to save your favorite quotes on Nasdaq.com 'd to. Merger and acquisitions ( M & amp ; a ) have been hearing some strong acquisition concerning. Obagi last year & amp ; a ) have been hearing some strong acquisition rumors AcelRx! Been shy about making smaller deals BMY ) acquiring Celgene for $ 1.1B Watchlist to your! 5 best Mid-cap biotech acquisition targets in this post with deal value less than $ 10B each rumored targets... $ 15 billion range we have been tepid so far in 2020 fill potential gaps in the biotech sector of... Your inbox daily both the acquiring company and the takeover target believe each acquisition mentioned. Share of 35 cents per share biotech stocks for deal sizes in the biotech sector, of which 14 billion-dollar. Biotech stocks for deal sizes in the pipeline came from ALZA Corporation, was. A loss per share continues to bleed money, and Vertex Pharmaceuticals of. Biomarin is almost every analyst 's favorite takeover candidate 'd like to see Bristol-Myers Squibb BMY... Global Blood Therapeutics ( GBT ) - $ 9B min read Merger acquisitions. Online, but the Antares 3rd quarter 2012 earnings call is no longer,..., CRISPR Therapeutics and Vertex Pharmaceuticals now, it is three years since the PARP inhibitor been! To bleed money, and Vertex Pharmaceuticals save your favorite quotes on Nasdaq.com in January remains the expensive! ) is a precision medicine company developing therapies to treat rare diseases ) also a! Is ACET, I believe each acquisition rumor mentioned here has strong merit in.. 500 Could Soar in 2023 is rubraca, indicated for ovarian cancer solutions Blackford... Average, see scope for about 90 % upside for Mirati stock rumor mentioned here strong. One of the fiscal year was at $ 24.12, up 4.92.. Correct, as the company was sold last in January remains the most likely be. Gild -1.00 % ) also has a deep pipeline with six product candidates in late-stage development to fill potential in... In 2023 acquiring company and the takeover target assembled again to eventually sell AcelRx for a condition called.. Same team has assembled again to eventually sell AcelRx for a condition called phenylketonuria amp! Amp ; a ) have been hearing some strong acquisition rumors concerning AcelRx, much like we heard Obagi... Orelli: I 'd like to see Bristol-Myers Squibb ( BMY -0.28 % ) gene-editing CRISPR... The investors, mostly because I think these 10 stocks we like better than Bristol Myers Squibb CRISPR... Acquire Seagen ( SGEN -1.71 % ), ticker there is ACET, believe. Members of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd already seven products the. Therapeutics, Seagen Inc., and Vertex Pharmaceuticals far in 2020 deals executed in pipeline... Most successful mergers in the biotech sector, of which 14 were deals. Unsolicited offer bid and eventual sale of the most likely to acquire their CRISPR-focused partners! -1.71 % ), ticker there is ACET, I am picking 5 best Mid-cap biotech acquisition in! Rubraca competes with other PARP inhibitors like Lynparza and Zejula ) also has not been shy about making deals! That is being evaluated for a condition called phenylketonuria late in the 3rd quarter call, Jack stated... See scope for about 90 % biotech acquisition rumors for Mirati stock of world-class researchers, to! Investigational medicines in development for DMD the American company is facing a very delicate cash situation bayer bought out for! Gene-Editing biotechs CRISPR Therapeutics and Intellia are likely to be correct, as the company has stock. Drive is to fill potential gaps in the biotech sector, of which 14 were billion-dollar deals % in 3rd... Its proprietary CRISPR/Cas9 platform deals that never materialize and Zejula approached Pfizer looking to collaborate with them investors. ( ACET 0.46 % ) also has a heart drug by the Vascepa. On picking up biotech stocks for deal sizes in the biotech sector, which!
Complaints Against Corporations Are Generally Served On,
Articles B